New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors.

Autor: Folk WP; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.; Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA., Kumari A; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.; Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA., Iwasaki T; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.; Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA.; Division of Signal Pathways, Biosignal Research Center, Kobe University, Kobe 657, Japan., Cassimere EK; Department of Biology, College of Science, Engineering and Technology, Texas Southern University, Houston, TX 77004, USA., Pyndiah S; Les Francs Bourgeois-La Salle, 75004 Paris, France., Martin E; Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA.; Department of Pathology, Medical College of Georgia, Augusta University Medical Center, Augusta, GA 30912, USA., Homlar K; Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA.; Department of Orthopaedic Surgery, Medical College of Georgia, Augusta University Medical Center, Augusta, GA 30912, USA., Sakamuro D; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.; Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2021 Dec 11; Vol. 22 (24). Date of Electronic Publication: 2021 Dec 11.

Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.

Autor: Folk WP; From the Biochemistry and Cancer Biology Graduate Program, Augusta University, Augusta, Georgia 30912.; the Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, Georgia 30912.; the Tumor Signaling and Angiogenesis Program, Georgia Cancer Center, Augusta University, Augusta, Georgia 30912., Kumari A; the Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, Georgia 30912.; the Tumor Signaling and Angiogenesis Program, Georgia Cancer Center, Augusta University, Augusta, Georgia 30912., Iwasaki T; the Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, Georgia 30912.; the Tumor Signaling and Angiogenesis Program, Georgia Cancer Center, Augusta University, Augusta, Georgia 30912.; the Division of Signal Pathways, Biosignal Research Center, Kobe University, Kobe 657, Japan., Pyndiah S; the Molecular Signaling Program, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112., Johnson JC; the Medicinal Chemistry and Molecular Pharmacology Graduate Program, Purdue University, West Lafayette, Indiana 47907, and., Cassimere EK; the Molecular Signaling Program, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112.; the Medicinal Chemistry and Molecular Pharmacology Graduate Program, Purdue University, West Lafayette, Indiana 47907, and., Abdulovic-Cui AL; the Department of Biological Sciences, College of Science and Mathematics, Augusta University, Augusta, Georgia 30904., Sakamuro D; From the Biochemistry and Cancer Biology Graduate Program, Augusta University, Augusta, Georgia 30912, dsakamuro@augusta.edu.; the Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, Georgia 30912.; the Tumor Signaling and Angiogenesis Program, Georgia Cancer Center, Augusta University, Augusta, Georgia 30912.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2019 Apr 05; Vol. 294 (14), pp. 5700-5719. Date of Electronic Publication: 2019 Feb 07.

[A new mechanism by which cancers can circumvent cisplatin resistance: The E2F1/BIN1 axis].

Autor: Pyndiah S; Université Paris-Est Créteil, Faculté de médecine, Inserm U955, Institut Mondor de recherche biomédicale, Créteil, France.

Publikováno v: Medecine sciences : M/S [Med Sci (Paris)] 2024 Mar; Vol. 40 (3), pp. 241-244. Date of Electronic Publication: 2024 Mar 22.

BIN1 in cancer: biomarker and therapeutic target.

Autor: Chen SY; Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China., Cao JL; Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China., Li KP; Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China., Wan S; Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China., Yang L; Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China. ery_yangli@lzu.edu.cn.

Publikováno v: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Aug; Vol. 149 (10), pp. 7933-7944. Date of Electronic Publication: 2023 Mar 09.

BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia.

Autor: Sudwarts, Ari^1,2 (AUTHOR), Ramesha, Supriya³ (AUTHOR), Gao, Tianwen³ (AUTHOR), Ponnusamy, Moorthi^1,2 (AUTHOR), Wang, Shuai^1,2 (AUTHOR), Hansen, Mitchell^1,2 (AUTHOR), Kozlova, Alena⁴ (AUTHOR), Bitarafan, Sara⁵ (AUTHOR), Kumar, Prateek³ (AUTHOR), Beaulieu-Abdelahad, David^1,2 (AUTHOR), Zhang, Xiaolin^1,2 (AUTHOR), Collier, Lisa^1,2 (AUTHOR), Szekeres, Charles² (AUTHOR), Wood, Levi B.⁵ (AUTHOR), Duan, Jubao^4,6 (AUTHOR), Thinakaran, Gopal^1,2 (AUTHOR) thinakaran@usf.edu, Rangaraju, Srikant³ (AUTHOR) srikant.rangaraju@emory.edu

Publikováno v: Molecular Neurodegeneration. 5/7/2022, Vol. 17 Issue 1, p1-27. 27p.